Summary: Researchers report that low levels of GABA-producing gut bacteria are associated with brain signatures linked to clinical depression. They suggest increasing these bacteria could offer a new avenue for treatment.

Source: Northeastern University

Gut Bacteria, GABA, and Clinical Depression: New Evidence Linking the Microbiome and the Brain

We often think of ourselves as independent individuals, but our bodies host trillions of microorganisms that influence health and behavior. Scientists estimate roughly 38 trillion microbes live on and inside us, especially in the gut, where they interact with our immune system, hormones, and nervous system.

New research led by Northeastern University finds a compelling association between specific gut bacteria and brain activity patterns seen in people with clinical depression. The study compared fecal samples and brain scans from individuals diagnosed with depression and identified a correlation between depressive brain signatures and lower abundance of certain Bacteroides species—gut microbes that can produce the inhibitory neurotransmitter gamma‑aminobutyric acid (GABA).

GABA is a key neurotransmitter that dampens electrical signaling between nerve cells, helping to prevent excessive neural excitation and contributing to calmness and emotional stability. When GABA signaling is impaired, people may be more susceptible to anxiety, sleep disturbances, and mood disorders such as depression. The researchers found that participants with reduced levels of Bacteroides bacteria—GABA producers—tended to display brain patterns commonly associated with depressive symptoms.

“If you have low levels of these GABA-producing bacteria, that is associated with brain signatures of depression,” said Kim Lewis, University Distinguished Professor of Biology. The team views this relationship as an intriguing starting point for exploring bacterium-based interventions that could boost GABA production in the gut and potentially influence brain function.

How the Gut and Brain Communicate

Scientists do not yet fully understand all pathways that connect the gut microbiome to the brain, but recent findings point to several mechanisms. Specialized cells in the intestinal lining, discovered in other recent studies, form direct physical connections with the vagus nerve, which runs from the brain to the abdomen. That nerve is a major communication route between the gut and the brain; researchers estimate roughly 80 percent of vagal signaling travels from the gut to the brain, relaying information about gut state and microbial activity.

In addition to vagal signaling, gut microbes can influence brain function through immune modulation and hormone pathways. Microbial metabolites, immune mediators, and hormone-like compounds produced in the gut can circulate systemically and affect brain circuits involved in mood and cognition.

A Unique GABA-Eating Microbe Helped Identify GABA Producers

The research team identified a previously unknown gut microbe that requires GABA to grow. They named it Evtepia gabavorous, or the “GABA-eater.” Because Evtepia gabavorous can only grow when GABA is available, it served as a biological detector: if this microbe flourished next to another bacterial species on a petri dish, that neighboring species was likely producing GABA.

“It’s remarkable,” Lewis said, noting that a bacterium specialized to consume only one compound—GABA—is exceptionally rare in microbiology. This discovery provided a practical method to screen gut bacterial species for GABA production and helped the team identify which microbes might influence host GABA levels.

Evidence from Other Studies and Next Steps

This study adds to a growing body of evidence connecting the microbiome to GABA levels and mood regulation. Earlier work found that transferring gut microbes from lean donors to obese recipients increased circulating GABA, and other preclinical studies show that certain bacteria-based treatments can elevate GABA and alter depression-like behaviors in rodents.

The researchers emphasize that many questions remain. They are pursuing larger human studies to test the hypothesis that manipulating gut bacterial communities—by increasing GABA-producing species or altering consumer–producer dynamics—could benefit people with depression.

To translate these findings into practical therapies, the study’s lead scientists co-founded a company focused on microbiome-based treatments. Their goal is to explore how targeted changes to microbial communities might contribute to mental health care while expanding our understanding of how microbiota shape human biology.

Institution: Northeastern University
Reporting author: Shannon Nargi
Publisher: NeuroscienceNews.com (coverage of the study)
Original research: Results were reported by the study team and are scheduled for publication in a peer-reviewed journal.